Articles published by TherapeuticsMD, Inc.

TherapeuticsMD Announces Second Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces First Quarter 2024 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Full Year 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Third Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Second Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces First Quarter 2023 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Third Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Additional $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces $7 Million Private Placement
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Second Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Expiration of Tender Offer
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD and EW Healthcare Partners Announce Definitive Agreement for EW Healthcare Partners to acquire TherapeuticsMD
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Receives U.S. Food and Drug Administration (FDA) Approval for Supplemental New Drug Application (sNDA) for ANNOVERA®
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces First Quarter 2022 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD to Report First Quarter 2022 Financial Results on May 16, 2022
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
U.S. Food and Drug Administration (FDA) Responds to Request From TherapeuticsMD to Revise Certain Manufacturing Testing Limits for ANNOVERA®
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Settles U.S. Patent Litigation with Amneal for BIJUVA® (Estradiol and Progesterone) — Allowing for a May 25, 2032 Generic Entry Date
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Third Quarter 2021 Financial Results
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Leadership Changes; Appointment of Industry Veteran, Hugh O’Dowd, as Chief Executive Officer
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD to Report Third Quarter 2021 Results on November 11, 2021
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Appointment of Mark Glickman as Chief Business Officer
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
Therapeutics MD Is Urging Women to ‘Take Pause’ During Menopause Awareness Month
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
TherapeuticsMD Announces Issuance of a J-Code for ANNOVERA® to Be Utilized in the Public Health Sector
From TherapeuticsMD, Inc.
Via Business Wire
Tickers TXMD
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.